Microcirculatory function in patients with arterial hypertension, metabolic syndrome and diabetes mellitus
Abstract
Aim. To assess microcirculatory (MC) function in patients with arterial hypertension (AH), AH and metabolic syndrome (MS), AH, MS and Type 2 diabetes mellitus (DM-2).
Material and methods. In total, 96 patients with Stage I-II AH and 26 healthy individuals were examined. All patients were divided into three groups: Group I (no clinical or laboratory evidence for MS and DM-2), Group II (MS), Group III (MS and DM-2). In all participants, lipid profile and forearm skin MC (laser Doppler flowmetry method) were assessed.
Results. Combination of AH and MS or DM-2 was associated with progressive MC deterioration (increased vasoconstriction, activated passive mechanisms of MC tonus regulation, reduced blood flow effectiveness due to non-capillary bypass, decreased tissue perfusion reserve, prevalent congestive and static MC types).
Conclusion. Modern methods of MC assessment in clinical practice provide additional objective information about disease severity and prognosis, which is especially important for patients with MS and DM-2.About the Authors
A. P. Vasilyev
Tumen Cardiology Center, Research Institute of Cardiology Institute, Tomsk Scientific Center, Siberian Branch, Russian Academy of Medical Sciences. Tumen, Russia
Russian Federation
Russian Federation
N. N. Streltsova
Tumen Cardiology Center, Research Institute of Cardiology Institute, Tomsk Scientific Center, Siberian Branch, Russian Academy of Medical Sciences. Tumen, Russia
Russian Federation
Russian Federation
M. A. Sekisova
Tumen Cardiology Center, Research Institute of Cardiology Institute, Tomsk Scientific Center, Siberian Branch, Russian Academy of Medical Sciences. Tumen, Russia
Russian Federation
Russian Federation
T. E. Savchuk
Tumen Cardiology Center, Research Institute of Cardiology Institute, Tomsk Scientific Center, Siberian Branch, Russian Academy of Medical Sciences. Tumen, Russia
Russian Federation
Russian Federation
References
1. Isomaa B, Almoton P, Iuonu I, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–9.
2. Ford IS, Gilas WN, Diotz WN. Prevalence of the metabolic syndrome among US adults tidings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287(3): 356–9.
3. Мамедов М.Н., Метельская В.А., Перова Н.В. Метаболический синдром: пути реализации атеротромболического потенциала. Кардиология 2000; 2: 83–9.
4. Оганов Р.Г., Александров А.А. Гиперинсулинемия и артериальная гипертония: возвращаясь к выводам United Kingdom Prospective Diabetes Study. РМЖ 2002; 11: 486–91.
5. Marks Jb, Raskin P. Cardiovascular risk in diabetes. J Diabet Complicat 2000; 14: 108–15.
6. Strocchi E. Hypertension and diabetes: prevalence and therapeutic challenges. J Hypertens 2001; 19(2): 227.
7. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2001; 24(1): 5–20.
8. Лазерная доплеровская флоуметрия микроциркуляции крови. Под ред. А.И. Курпаткина, В.В. Сидоренко: Рук-во для врачей. Москва, ОАО Изд-во “Медицина” 2005.
9. Микроциркуляция в кардиологии. Под ред. В.И. Маколкина Москва 2004.
10. Julius S, Gudrabrandsson T, Jamerson K, et al. The interconnection between sympathetics, microcirculation, and insulin resistance in hypertension. Blood Pressure 1992; 1: 9–19.
11. Modan M, Halkin H. Hyperinsulinemia or increased sympathetic drive as a links for obesity and hypertension. Diabetes Care 1991; 14: 470–87.
12. Doria A, Fioretto P, Avogaro A, et al. Insulin resistance is associated with high sodium-lithium countertransport in essential hypertension. Am J Physiol 1991; 261: 684–91.
13. Cicha I, Suzuki Y, Tateishi N, et al. Enhancement of red blood cell aggregation by plasma triglycerides. Clin Hemorheol Microcircul 2000; 24(4): 247–55.
14. Pfeifle B, Ditschuneit H. Effect of insulin on groth of cultured human arterial smooth muscle cells. Diabetologia 1981; 20: 155–8.
15. Балаболкин М.И., Мамаева Г.Г., Трошкина Е.А. Использование лазерного доплеровского расходомера в целях ранней диагностики диабетических микроангиопатий. Метод флоумет 1997; 29–34.
16. Манухина Е.Б., Малышев И.И., Архипенко И.В. Оксид азота в сердечно-сосудистой системе: роль в адаптационной защите. Вестник РАМН 2000; 4: 16–21.
17. Zimny S, Dessel F, Ehren M. Early detection of microcirculatory impairment in diabetic patients with foot at risk. Diabetes Care 2001; 24: 1810–4.
18. Балаболкин М.И. Диабеталогия. Москва “Медицина” 2000.
19. Лобанкова Л.А., Котовская Ю.В., Мильто А.С. и др. Особенности структурно-функционального состояния микроциркуляторного русла у больных артериальной гипертонией и сахарным диабетом 2-го типа. Артер гиперт 2005; 3: 177–81.
20. Kollros PR, Konkle BA. Microvascular disease in diabetes mellitus. J Cardiovasc Risk 1997; 46: 70–5.
21. Klein R, Klein B, Moss S. Cruickshanks K. Association of ocular disease and mortality in a diabetic population. Arch Ophthalmol 1999; 117: 1487–95.
22. Kemp HK. Syndrome-X revisited. JACC 1991; 17: 507–8.
23. Rosenson RS. Statin therapy: new therapy for cardiac microvascular dysfunction. Eur Heart J 2003; 24: 1993–4.
24. Albertal M, Regar E, Van Langenhove G, et al. Оn behalf of the DEBATE investigators. Flow velocity and predictors of suboptimal coronary flow velocity reserve after coronary balloon angioplasty. Eur Heart J 2002; 23: 133–8.
25. Nishida T, Di Mario C, Kern MJ, et al. Impact of final coronary flow velocity reserve on late outcome following stent implantation. Eur Heart J 2002; 23: 331–40.
26. Александров А.А., Чукаева И.И. Микроциркуляторная ишемия и статины: уроки интервенционной кардиологии. РФК 2007; 1: 48–54.
Review
For citations:
Vasilyev A.P., Streltsova N.N., Sekisova M.A., Savchuk T.E. Microcirculatory function in patients with arterial hypertension, metabolic syndrome and diabetes mellitus. Cardiovascular Therapy and Prevention. 2008;7(5):24-29. (In Russ.)
Views:
545
Email this article 
